3,4-Methylenedioxyphentermine

3,4-Methylenedioxyphentermine (MDPH) is a lesser-known drug of the amphetamine family. MDPH was first synthesized by Alexander Shulgin. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDPH.

3,4-Methylenedioxyphentermine
Names
Preferred IUPAC name
1-(2H-1,3-Benzodioxol-5-yl)-2-methylpropan-2-amine
Other names
MDP; MDPH; 3,4-Methylenedioxyphentermine;
3,4-Methylenedioxy-alpha,alpha-dimethyl-1-ethane
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C11H15NO2/c1-11(2,12)6-8-3-4-9-10(5-8)14-7-13-9/h3-5H,6-7,12H2,1-2H3 ☒N
    Key: OIZBHKBNZXRXSM-UHFFFAOYSA-N ☒N
  • InChI=1/C11H15NO2/c1-11(2,12)6-8-3-4-9-10(5-8)14-7-13-9/h3-5H,6-7,12H2,1-2H3
    Key: OIZBHKBNZXRXSM-UHFFFAOYAY
  • NC(C)(C)CC1=CC(OCO2)=C2C=C1
Properties
C11H15NO2
Molar mass 193.246 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

In his book PiHKAL (Phenethylamines i Have Known And Loved), the dosage range is listed as 160–240 mg, and the duration as 3–5 hours.[1] MDPH's effects are very similar to those of MDA: they both are smooth and "stoning," and do not cause any visuals. They also alter dreams and dream patterns. Shulgin describes MDPH as a promoter; it promotes the effects of other drugs, similarly to 2C-D.

The N-methyl derivative, 3,4-methylenedioxy-N-methylphentermine (MDMPH), has been described by Shulgin as lacking MDMA-like effects.[2] Accordingly, MDMPH, as well as MDPH, were found to be inactive as serotonin releasing agents in vitro.[2][3]

Legality

edit

United Kingdom

edit

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[4]

See also

edit

References

edit
  1. ^ MDPH entry in PiHKAL
  2. ^ a b Nichols, David F.; Oberlender, Robert (1990). "Structure-Activity Relationships of MDMA and Related Compounds: A New Class of Psychoactive Agents?". Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. Vol. 9. Boston, MA: Springer US. p. 105–131. doi:10.1007/978-1-4613-1485-1_7. ISBN 978-1-4612-8799-5.
  3. ^ Nichols DE, Lloyd DH, Hoffman AJ, Nichols MB, Yim GK (May 1982). "Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes". J Med Chem. 25 (5): 530–535. doi:10.1021/jm00347a010. PMID 7086839.
  4. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.